cdr

Hot Keywords
Drug Resistance Mechanisms Epigenetic Resistance in Cancer Therapy Biomarkers Pharmacogenetics of Cancer Liquid Biopsy Targeted Cancer Therapy Non-coding RNAs Kinase Inhibitors ABC Transporters

Top

News

  • The First Editorial Board Meeting of Cancer Drug Resistance Successfully Held

    The first Editorial Board meeting of Cancer Drug Resistance (CDR) was successfully held on 21st September 2022. Twenty-eight Editorial Board members attended the meeting and witnessed the progress and breakthroughs of CDR in 2022.
    Published on: 27 Sep 2022 Viewed: 27
  • The Discussion Between Prof. Masakazu Toi and Dr. Ravi Velaga on Breast Cancer

    On September 2, 2022, the Editorial Office was delighted and honored to have a special interview with Prof. Masakazu Toi and Dr. Ravi Velaga from Kyoto University, Japan.
    Published on: 8 Sep 2022 Viewed: 459
  • Special Interview with Prof. Jacqueline Cloos

    On 15 August 2022, the Editorial Office was very honored to interview Prof. Jacqueline Cloos, a full professor in the Department of Hematology at Cancer Center Amsterdam, Netherlands.
    Published on: 22 Aug 2022 Viewed: 252
  • Special Interview with Prof. Marina Y. Konopleva

    Acute myeloid leukemia (AML) is a malignancy of the stem cell precursors of the myeloid lineage (red blood cells, platelets, and white blood cells other than B and T cells). Thus, it is important to develop new and evolving therapies that raise hope for improved survival and less toxic treatment.
    Published on: 17 Aug 2022 Viewed: 288
  • Cancer Drug Resistance is selected to be included in Emerging Sources Citation Index(ESCI)

    On August 10, 2022, Cancer Drug Resistance (CDR, 2578-532X (Online)) is selected to be included in Emerging Sources Citation Index (ESCI), which marks a significant milestone in the development of CDR.
    Published on: 11 Aug 2022 Viewed: 702
  • Exclusive Interview with Prof. Guru P. Sonpavde - Guest Editor of the Special Issue "Resistance to Systemic Therapies in Renal Cell Carcinoma"

    Renal cell carcinoma (RCC) is a highly vascularized tumor and prone to distant metastasis, the prospect potential approaches to overcome RCC resistance is important to guide individualized and precision drug therapy.
    Published on: 15 Jul 2022 Viewed: 288
  • The First Youth Editorial Board Meeting of Cancer Drug Resistance Successfully Held

    The first Youth Editorial Board Member Meeting of Cancer Drug Resistance (CDR) was held on 31st May 2022. Eighteen scientists from nine different countries actively participated in the one-hour online meeting Via Zoom.
    Published on: 16 Jun 2022 Viewed: 180
  • Cancer Drug Resistance indexed in PubMed Central

    On May 17, 2022, Cancer Drug Resistance (CDR, 2578-532X (Online)), an OAE journal, passed the scientific quality review process of the U.S. National Institutes of Health's National Library of Medicine (NIH/NLM), and is now officially indexed in PubMed Central® (PMC). This will greatly enhance the international influence of CDR.
    Published on: 17 May 2022 Viewed: 918
  • CDR 2019 Best Paper Award Announcement

    The editorial Office of Journal Cancer Drug Resistance (CDR) would like to announce that the publication "Drug resistance and combating drug resistance in cancer" has been awarded as "CDR 2019 Best Paper".
    Published on: 10 May 2022 Viewed: 369
  • Congratulations to Dr. Vittoria Raimondi for Winning the Best Presentation Award at The SOHO Italy Conference

    The SOHO Italy Conference was successfully held on September 27-30, 2021, in Rome, Italy. The journal Cancer Drug Resistance supported the awards for the best presentation of the meeting.
    Published on: 5 Nov 2021 Viewed: 621
  • Congratulations to Dr. Kok Yung Lee and Dr. Anna Mueller-Schoell for Winning the Best Presentation Award at the EORTC-PAMM Group Meeting

    The EORTC-PAMM Meeting was successfully held on 21-22 April 2021, and the journal Cancer Drug Resistance supported two awards for the best presentation on each day of the meeting.
    Published on: 16 Jun 2021 Viewed: 954
  • Acknowledgment to Reviewers in 2020

    We would like to sincerely thank each and every reviewer who dedicated his or her time to reviewing manuscripts for Cancer Drug Resistance (CDR) in 2020. In the review process, at least two experts contribute comments about each paper published in CDR.
    Published on: 12 Mar 2021 Viewed: 846
  • Cancer Drug Resistance Indexed in Scopus

    On 4th March, the Editorial Office received the pleasant news from Scopus Title Evaluation Support that Cancer Drug Resistance (CDR, ISSN:2578-532X (Online)) had been indexed in Scopus databse after rigorously evaluated by the Content Selection & Advisory Board (CSAB).
    Published on: 8 Mar 2021 Viewed: 2871
  • Recruitment of Junior Editorial Board Members

    To provide young scholars with an active academic exchange platform for exchanging ideas with each other and with influential experts in cancer drug resistance, and cultivate candidates for Editorial Board of Cancer Drug Resistance (CDR), the Editorial Office plans to recruit junior Editorial Board members worldwide from now on.
    Published on: 22 Oct 2020 Viewed: 2403
  • The Work of Expanding the Editorial Board of CDR has come to a Successful Conclusion

    As of August 28, 2020, the three-month work of expanding the Editorial Board of Cancer Drug Resistance (CDR) has come to a successful conclusion. A total of 30 scientists with significant international influence in the field of cancer drug resistance joined the Editor Board, with the ambition to help create a better future for CDR.
    Published on: 28 Aug 2020 Viewed: 1188
  • Acknowledgment to Reviewers in 2019

    Rigorous and impartial peer-review process is very essential for success of a journal. We would like to sincerely thank each and every reviewer who dedicated his or her time and expertise to reviewing manuscripts for Cancer drug resistance (CDR) in 2019.
    Published on: 3 Feb 2020 Viewed: 1530
  • New Year's Blessings from Editorial Office of Cancer Drug Resistance

    New Year's Blessings from Editorial Office of Cancer Drug Resistance
    Published on: 21 Jan 2020 Viewed: 999
  • AACR 2020 Annual Meeting - We Are Coming!

    We would like to tell you that Cancer Drug Resistance (CDR), together with two sister journals Journal of Cancer Metastasis and Treatment (JCMT) and Hepatoma Research (HR), will attend AACR 2020 Annual Meeting as the leading journal! Welcome to visit us at Booth #1410!
    Published on: 21 Jan 2020 Viewed: 1170
  • Cancer Drug Resistance Is Now a Member of the Committee on Publication Ethics

    We are pleased to announce that the journal of Cancer Drug Resistance is Now a member of the Committee on Publication Ethics (COPE). Please see details at: https://publicationethics.org/members/cancer-drug-resistance
    Published on: 15 Mar 2019 Viewed: 2457
  • The 2018 Annual Report of Cancer Drug Resistance

    Since the first issue of Cancer drug resistance (CDR) officially published on March 19, 2018, more and more scholars pay attention to this journal and inspired by the journal's achievement throughout the year. In 2018, CDR has totally published 20 papers of which have been cited 14 times within this year.
    Published on: 31 Jan 2019 Viewed: 2484
  • Acknowledgment to Reviewers

    We would like to sincerely thank each and every reviewer who dedicated his or her time and expertise to reviewing manuscripts for Cancer drug resistance (CDR). In the review process, at least two experts contribute comment about each paper published in CDR, without their help, we would not be as fast-growing as it is today. Thus, the Journal of Cancer Drug Resistance acknowledge with particular gratitude the following reviewers who give freely of their support during the period March 2018-December 2018.

    Published on: 17 Jan 2019 Viewed: 1278
  • Special Issue eBooks

    We now offer an article collection of Cancer drug resistance (CDR) Speical Issues to our authors, which are freely available for download on our website. If you are the Guest Editor of any of these Special Issues, please feel free to contact us for the printed version of the Ebooks. Your kind promotion of this collection through either conferences or other means would be highly appreciated.

    Published on: 16 Jan 2019 Viewed: 1431
  • The First Strategic Planning Symposium of Cancer Drug Resistance

    For the future development, Cancer Drug Resistance (Cancer Drug Resist) held its first strategic planning symposium on August 26, 2016 and all team members joined it. This meeting aimed to discuss the planning and development strategies by inviting Prof. Peters. According to the orientation of the journal, Prof. Peters said that current academic journals on cancer drugs cover many areas on drug metabolism, pharmacology, drug actions, drug development, biomarkers and many more items, but a specific journal on cancer drug resistance does not exist, except for a general review journal Drug Resistance Update. Therefore, he expects that the planned journal has a great development prospect.
    Published on: 19 Sep 2017 Viewed: 3267
© 2016-2022 OAE Publishing Inc., except certain content provided by third parties